NTLA
NasdaqINTELLIA THERAPEUTICS, INC.
Basic Materials · In Vitro & In Vivo Diagnostic Substances
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$2.9M
2021
$11.4M
2022
$6.6M
2023
$57.9M
2024
$67.7M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$67.7M
Net Income$-412.7M
Gross Profit—
Oper Income$-441.0M
EPS (dil)$-3.81
Rev/sh$0.48
FCF/sh$-2.83
Book/sh$4.81
Gross M—
Oper M-651.7%
Profit M-609.9%
FCF M-585.0%
ROE-61.5%
ROA-49.0%
ROIC-85.5%
R&D/Rev574.6%
Rev Y/Y16.9%
Rev 3Y CAGR81.1%
EPS Y/Y27.4%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+9.6%
Current Ratio5.08
Quick Ratio—
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$155.5M
Total Assets$842.1M
Oper CF$-394.7M
Capex$1.1M
Free CF$-395.9M
Buybacks—
Equity$671.4M
Liabilities$170.7M
Shs Outstand0.14B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.9M | $11.4M | $6.6M | $57.9M | $67.7M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-267.9M | $-458.2M | $-515.3M | $-534.3M | $-441.0M |
| Net Income | $-267.9M | $-474.2M | $-481.2M | $-519.0M | $-412.7M |
| Diluted EPS | $-3.78 | $-6.16 | $-5.42 | $-5.25 | $-3.81 |
| Operating Cash Flow | $-225.0M | $-333.3M | $-394.1M | $-348.9M | $-394.7M |
| Free Cash Flow | $-237.8M | $-346.8M | $-408.1M | $-354.7M | $-395.9M |
COMMUNITY · $NTLA0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.